Prognostic factors in prostate cancer: College of American Pathologists Consensus Statement 1999

Archives of Pathology and Laboratory Medicine

Volumn 124, Issue 7, 2000, Pages 995-1000

  Bostwick, David G ^a   Grignon, David J ^b   Hammond, M Elizabeth H ^c   Amin, Mahul B ^d   Cohen, Michael ^e   Crawford, David ^f   Gospadarowicz, Mary ^g   Kaplan, Richard S ^h   Miller, Daniel S ⁱ   Montironi, Rodolfo ^j   Pajak, Thomas F ^k   Pollack, Alan ^l   Srigley, John R ^m   Yarbro, John W ⁿ   Schramm, Joe ^o  

^a BOSTWICK LABORATORIES   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^j UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^k AMERICAN COLLEGE OF RADIOLOGY   (United States)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m MCMASTER UNIVERSITY   (Canada)

ⁿ American Joint Committee on Cancer   (United States)

^o Molecular Pathology Division   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER STAGING; CONFERENCE PAPER; DATA ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; NEEDLE BIOPSY; PATIENT CARE; PLOIDY; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR;

CELL NUCLEUS; DNA, NEOPLASM; HUMANS; LYMPHATIC METASTASIS; MALE; PATHOLOGY, CLINICAL; PLOIDIES; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOCIETIES, MEDICAL; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 12944332009     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Partin AW, Kattan MW, Subong ENP, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA. 1997;277:1445-1451.
2. Lankford SP, Pollack A, Zagars GK. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy. Int J Radiat Oncol Biol Phys. 1997;38:327-333.
3. Pisansky TM, Kahn MJ, Rasp GM, et al. A multiple prognostic index predictive of disease outcome following irradiation for clinically localized prostate carcinoma. Cancer. 1997;79:337-344.
4. Roach M III, Marquez C, Hae-Sook Y, et al. Predicting the risk of lymph node involvement using the pretreatment prostate-specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Physiol. 1994;28:33-37.
5. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-374.
6. Kattan MW, Stapleton AMF, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer. 1997;79:528-537.
7. Bostwick DG, Montironi R. Evaluating radical prostatectomy specimens: therapeutic and prognostic importance. Virchow Arch. 1997;430:1-16.
8. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Semin Surg Oncol. 1994;10:60-72.
9. Bova GS, Fox WM, Epstein JI. Methods of radical prostatectomy specimen processing: a novel technique for harvesting fresh prostate cancer tissue and review of processing techniques. Mod Pathol. 1993;6:201.
10. Coden MB, Soloway MS, Murphy WM. Sampling of radical prostatectomy specimens: how much is adequate? Am J Clin Pathol. 1994;101:250-252.
11. D'Amico AV, Whittington R, Malkowicz SB, et al. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized disease. J Urol. 1998;160:2096-2101.
12. Dillioglugil O, Leibman BD, Kattan MW, Seale-Hawkins C, Wheeler TM, Scardino PT. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 1997;50:93-99.
13. Egevad L, Engstrom K, Busch C. A new method for handling radical prostatectomies enabling fresh tissue harvesting, whole mount sections and landmarks for alignment of sections. J Urol Pathol. 1998;9:17-28.
14. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993;71:3582-3593.